CATX 241220 5.00P (CATX241220P5000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

CATX241220P5000

Watchlist

2.30
0.000.00%

15min DelayTrading Dec 20 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
GlobeNewswireNov 27, 2024 07:00 ET
Insider Purchase: CEO of $CATX (CATX) Buys 6,600 Shares
Quiver QuantitativeNov 26, 2024 07:15 ET
Perspective Therapeutics Downgraded to Neutral From Buy at BofA
Yahoo FinanceNov 26, 2024 06:45 ET
Perspective Therapeutics Is Maintained at Outperform by RBC Capital
Dow JonesNov 25, 2024 10:55 ET · Ratings
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6
Moomoo NewsNov 25, 2024 10:33 ET · Ratings
B of A Securities Downgrades Perspective Therapeutics to Neutral, Lowers Price Target to $6
BenzingaNov 25, 2024 08:05 ET · Ratings

Comments

Jaguar8

Nov 22, 2024 13:52

Easy 16% 😉

$Perspective Therapeutics (CATX.US)$

Johnny Mnemonic

Nov 22, 2024 10:12

I don't trust nobody
I don't even trust my mind
losing everybody
they can never take my grind

Jaguar8

Nov 21, 2024 23:09

On watchlist. Reason: Presentation today. Possible PR tomorrow

$Perspective Therapeutics (CATX.US)$

Stock_Drift

Nov 15, 2024 16:17

After Hours Ticks. 5:16pm 11/15🦌

$Scorpius Holdings (SCPX.US)$ $Perspective Therapeutics (CATX.US)$ $Turbo Energy (TURB.US)$ $Adverum Biotechnologies (ADVM.US)$ $NFT Ltd (MI.US)$ $Xylo Technologies (XYLO.US)$ $Lipocine (LPCN.US)$ $Massimo (MAMO.US)$ $China Jo-Jo Drugstores (CJJD.US)$ $Edesa Biotech (EDSA.US)$ $Atara Biotherapeutics (ATRA.US)$ $Eterna Therapeutics (ERNA.US)$ $DDC Enterprise (DDC.US)$
📊⚡️📊

Trytosaveabit

Nov 15, 2024 15:13

Watching! Note the dates!

$Perspective Therapeutics (CATX.US)$ Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium t...